The effect of changing to Bictegravir on lipids using real world data: A brief report

Heseltine, Thomas, Hughes, Elen, Mathew, Jean, Murray, Scott and Khoo, Saye ORCID: 0000-0002-2769-0967
(2022) The effect of changing to Bictegravir on lipids using real world data: A brief report. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 47 (12). pp. 2182-2187.

[img] Text
paper4_v6.docx - Author Accepted Manuscript

Download (364kB)


<h4>What is known and objective</h4>Cardiovascular disease is of increasing concern in patients living with HIV. The significant advancement in antiretroviral treatment has ensured that patients are now succumbing to traditional diseases of ageing. First generation antiretroviral therapy caused multiple side effects including significant dyslipidaemia. Despite the advancement and improving safety profile of treatment concerns remain about antiretroviral induced dyslipidaemia. We sought to investigate the real-world effect on lipids in patients switching to a Bictegravir based regime.<h4>Methods</h4>We conducted a retrospective analysis in patients switching therapy to Biktarvy at the Royal Liverpool University Hospital. Data was collected from the HIV database that is established for clinical use, as an electronic patient record, and audit purposes. Lipid data was cross checked with the Trust electronic reporting system. Participants were included if they were HIV-positive, >18 years and had switched to Biktarvy Patients were also required to have a lipid profile available 52 weeks prior to switching and 100 weeks post switching. Summary statistic were calculated and multiple regressions models were constructed to assess the independent predictors of lipid change. We also performed one way analysis of covariance (ANCOVA) to assess the impact of switching therapy on each quartile of the baseline lipid panel.<h4>Results and discussion</h4>There were 135 patients included in the analysis with a mean age of 47. The majority of the population were male (80%). At a mean follow up of 42 weeks post switch there was no significant difference in total cholesterol (p = 0.64), triglyceride (p = 0.64) or high density lipoprotein (HDL) cholesterol (p = 0.08). In the regression analysis the highest quartile of baseline total cholesterol and triglyceride were independently associated with improvement in lipid markers. Switching from protease inhibitor therapy was also significantly associated with improvement in triglyceride. In addition, the ANCVOA demonstrated that the highest quartiles of total cholesterol, triglyceride and the lowest quartile of HDL were associated with significant improvement in lipid markers after switching to Bictegravir.<h4>What is new and conclusion</h4>We demonstrated that patients with the most adverse lipid profiles at baseline had significant improvements in lipid profiles. In addition, patient switching away from protease inhibitor therapy also had significant improvements in triglyceride.

Item Type: Article
Uncontrolled Keywords: Bictegravir, cardiovascular disease, HIV, lipid change
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 22 Jun 2023 15:13
Last Modified: 02 Nov 2023 02:30
DOI: 10.1111/jcpt.13789
Related URLs: